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Abstract
Background: Most patients with Posttraumatic Stress Disorder (PTSD) suffer residual symptoms following first-line
treatment. Oxidative stress has been implicated in the pathophysiology of PTSD. N-acetylcysteine (NAC) is a
precursor of the brain’s primary antioxidant, glutathione, and may diminish oxidative cellular damage. An 8-week
pilot study of NAC in veterans with PTSD found that symptoms were significantly reduced in the NAC group
compared to placebo. This study aims to confirm these findings with a larger sample in a double-blind, placebo-
controlled trial to further explore the efficacy of NAC as an adjunctive therapy in treatment-resistant PTSD.
Methods: A multicentre, randomised, double-blind, placebo-controlled trial for adult patients who still meet criteria
for PTSD following first-line treatment. The intervention comprises either NAC as a fixed dose regime of 2.7 g/day
(900mg three times daily) administered orally for 12 weeks, or placebo. Standard care for PTSD will continue in
addition, including other pharmacotherapies. Detailed clinical data will be collected at randomisation and weeks 4, 8,
12, 16, and 64 post-randomisation, with self-report measures completed weekly from baseline to 16 weeks and at 64
weeks post-randomisation. Blood-based biomarkers will be collected at baseline and 12weeks to assess the
mechanism of effect. The primary outcome measure will be change in Clinician-Administered PTSD Scale for DSM-5 at
12 weeks compared with baseline. Secondary outcomes will be change in quality of life, depression, anxiety, substance
use and craving, and somatic symptoms. With 126 completed participants (63 per arm), the study is powered at 80%
to detect a true difference in the primary outcome measure using a two-tailed analysis with alpha = 0.05, beta = 0.2.
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Discussion: This is the first multicentre, double blind, randomised, placebo-controlled trial of adjunctive NAC for
treatment-resistant PTSD. NAC has an established safety profile, is readily available and easy to administer, and has a
favourable tolerability profile, therefore making it an attractive adjunctive therapy. Inclusion of blood analyses to assess
potential target engagement biomarkers of oxidative stress and neuroinflammation may help gauge the biological
mechanisms of effect of NAC.
Trial registration: ACTRN12618001784202, retrospectively registered 31/10/2018, URL: http://www.anzctr.org.au/Trial/
Registration/TrialReview.aspx?id=376004.
Keywords: Clinical trial protocol, N-acetyl cysteine, Post-traumatic stress disorder, N-acetyl cysteine, Adjunctive therapy,
Randomised clinical trial, Oxidative stress, Biomarker
Background
Posttraumatic Stress Disorder (PTSD) is a condition
characterized by re-experiencing of trauma, deterioration
in cognition and mood, avoidance of triggers and hyper-
arousal symptoms after experiencing severely threatening,
traumatic events [1]. Large community surveys suggest
that most people will experience at least one potentially
traumatic event in their lives [2], however in a proportion
of individuals, symptoms of psychological distress persist
and progress to the development of PTSD. PTSD affects
approximately 6% of the population, though rates are con-
siderably higher for certain occupational groups such as
emergency service workers and military personnel [3]. It is
difficult to treat, with only a quarter of patients achieving
full remission with first-line therapy [4].
PTSD is associated with substantial disability as symp-
toms are usually chronic [5] and accompanied by extensive
functional decline, including high rates of unemployment
[6], family and relationship difficulties [7], suicidality [8]
and reduced quality of life [9]. PTSD is also frequently asso-
ciated with a variety of comorbidities such as depression,
substance abuse and psychosomatic disorders [1]. Recom-
mended first-line treatments of PTSD in Australia are psy-
chological, including trauma-focused psychotherapy, but
they suffer from limited tolerability, and many patients dis-
continue treatment prematurely [10]. Selective-serotonin
reuptake inhibitors (SSRIs) are the preferred pharmaco-
logical intervention for PTSD, either as alone or in conjunc-
tion with psychological therapies [11, 12]. SSRIs have
demonstrated only moderate efficacy, however, with the
majority of patients failing to achieve remission even when
combined with psychotherapy [13, 14]. Those who do not
respond to first-line treatment are usually considered
treatment-resistant, and by this measure up to 70% of pa-
tients with PTSD fall into that category [15].
Several lines of evidence suggest that increased oxida-
tive stress and neuroinflammation are implicated in the
pathophysiology of PTSD [16–18]. Oxidative stress oc-
curs when there are excess levels of free radicals, or in-
adequate antioxidants, potentially leading to cellular
damage. Multiple studies in PTSD samples have
demonstrated elevated levels of biomarkers of oxidative-
stress, including anti-oxidant blood-based enzyme con-
centrations and altered gene expression [19, 20]. The
brain’s primary antioxidant, glutathione, is dysregulated
in patients with PTSD, [21] and downregulation of the
Glutathione-S-Transferase Mu1 & 2 genes, responsible
for encoding enzymes involved in conjugation reactions
with glutathione, is considered the most reliable blood-
based biomarker for PTSD [22]. Replenishing glutathi-
one could be expected to diminish oxidative cellular
damage, and hence potentially ameliorate PTSD symp-
toms and prevent long-term illness sequelae. However,
glutathione is not orally bioavailable. In order to restore
glutathione supply, its synthesis must be enhanced, for
example by a precursor such as N-acetylcysteine (NAC).
Research indicates that NAC, or more likely its metab-
olites, can cross the blood-brain barrier [23, 24] and sys-
temic delivery leads to a rise in brain glutathione [25].
While emerging evidence supports the use of NAC in
the treatment of other psychiatric disorders [26, 27], this
has yet to be thoroughly explored in PTSD. A small pilot
study assessing NAC as an adjunct to cognitive-
behavioural therapy in a group of US veterans with co-
morbid substance use disorders demonstrated significant
reductions in self-reported PTSD symptoms, co-morbid
depressive symptoms and cravings for substance use
compared to the placebo group. In view of these findings
and the growing understanding of theoretical founda-
tions of oxidation biology, NAC appears well placed as a
potential adjunctive treatment for PTSD. It is well-
tolerated [28, 29], low cost and is available without pre-
scription. To date, NAC has yet to be evaluated in a
large scale, randomised clinical trial as an adjuvant treat-
ment for PTSD.
Study objectives
This study aims to investigate the efficacy of adjunctive
NAC for patients with treatment-resistant PTSD. It is
hypothesised that NAC plus treatment as usual, will be
superior to placebo plus treatment as usual in reducing
clinician-assessed PTSD symptoms in an adult PTSD
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sample. It is also hypothesised that adjunctive NAC will
result in a reduction in self-reported PTSD, depressive
and somatic symptoms, substance use and cravings, and
improvement in quality of life. This study will also ex-
plore blood-based biomarkers in PTSD to elucidate the
mechanisms of action of NAC on PTSD symptoms.
Methods
Study design and setting
This study is a multi-site, 12-week, double-blind, rando-
mised, placebo-controlled trial. The trial will be con-
ducted at two tertiary mental-health centres in Australia
which provide specialist PTSD treatment services:
Austin Health’s public Psychological Trauma Recovery
Service (PTRS) and The Melbourne Clinic (TMC) which
is a private psychiatric hospital. Both sites acquired eth-
ics approval to allow recruitment of participants from
their clinical services and from the general community.
Patient and public involvement
Patients or the public were not involved in the design, or
conduct, or reporting, or dissemination plans of this
study.
Patients
Eligibility criteria are outlined in Table 1. The target
population includes individuals aged 18 and older who
meet Diagnostic & Statistical Manual of Mental Disorders
- Fifth edition (DSM-5) diagnostic criteria for current
PTSD despite having undergone a recommended course
of treatment. A treatment course is defined as a full course
of trauma-focused psychotherapy or a 6-week (minimum)
course of pharmacotherapy (SSRI or SNRI). Participants
may continue their usual treatments during the study.
Participants must have the capacity to consent to the
study and to follow its instructions and procedures.
Sample size calculation and recruitment target
The target sample size is 126 participants (63 per arm).
For a two-tailed analysis with alpha = 0.05, beta = 0.2, the
study is powered at 80% to detect a true difference in
CAPS-5 scores between the NAC and placebo groups of
10+/− 20 points. In our pilot trial, effect sizes for PTSD
symptoms as well as all secondary measures exceeded
this threshold. Using a conservative attrition rate of one-
third, we will need to recruit 190 participants to have
126 complete the trial and follow-up.
The study aims to recruit participants referred by their
treating clinician or self-referred from the community. A
summary of the participant flow through the study is
shown in Fig. 1.
Screening phase and baseline assessment
Individuals with PTSD who express interest in partici-
pating in the study will be contacted by a trial clinician
and screened according to the eligibility criteria outlined
in Table 1 via a brief telephone interview.
After initial telephone screening, eligible participants
will be invited to a face-to-face or videoconference 90-
min clinical interview. After obtaining IRB-approved
written informed consent, a diagnosis of PTSD will be
confirmed through the Clinician-Administered PTSD
Scale for DSM-5 (CAPS-5) – monthly version, which is
the gold-standard in PTSD assessment. Participants will
be excluded if they do not meet diagnostic criteria for
current PTSD. If patients are deemed eligible and are
enrolled in the study, this interview will constitute part
of the baseline assessment.
The baseline assessment will also include data collec-
tion via clinician-administered and self-reported ques-
tionnaires regarding psychiatric comorbidities, PTSD
symptoms, quality of life, substance use and somatic
symptoms (see Table 2). Detailed clinical and demo-
graphic information will be collected on all participants
at the baseline clinical interview. This will include age,
Table 1 Inclusion and Exclusion Criteria
Inclusion criteria Exclusion criteria
Age≥ 18 and able to provide written informed consent Already taking NAC, selenium or vitamin E
History of anaphylactic reaction to NAC
Current PTSD
Meets criteria for DSM-5 diagnosis of PTSD according to
CAPS-5 monthly version




Treatment resistant PTSD defined as
(a) Minimum 1x trial of an antidepressant (SSRI or SNRI)
for minimum 6weeks without adequate response OR (b)
completed a course of trauma-focused psychotherapy
Currently pregnant or breastfeeding
Planning to conceive a child during the trial or 3 months following
If currently taking an antidepressant medication
• Minimum of 6-weeks if recently initiated
• Dose must be stable for minimum 2 weeks
History of psychotic illness
NAC N-acetyl cysteine, PTSD Posttraumatic Stress Disorder, DSM-5 Diagnostic & Statistical Manual of Mental Disorders Fifth edition, CAPS-5 Clinician-Administered
PTSD Scale for DSM-5, SSRI Selective-serotonin reuptake inhibitor, SNRI Serotonin and norepinephrine reuptake inhibitor
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gender, marital status, years of formal education, service
history, receipt of state benefits, ethnicity, and country
of birth.
Participants will be provided with a signed copy of
their information and consent form which includes writ-
ten information regarding study protocol, purpose, data
handling, participant confidentiality, potential side-
effects and their right to withdraw from the study at any
time.
Allocation
Randomisation will take place only once participants
have undertaken the baseline assessment and are
confirmed eligible for the trial. If all inclusion and exclu-
sion criteria are satisfied, trial participants will be rando-
mised at a 1:1 ratio to the NAC (treatment) or placebo
arm. Random block allocation of medication packs will
be in a four-to-a-block design, randomly generated by a
computer program. Randomisation will be carried out
by the clinical trial pharmacy service at the trial site. Al-
location will be concealed from participants and all other
research staff as the study is double blinded.
A fixed dose regime of 2.7 g/day of NAC will be ad-
ministered as 900 mg three times daily for 12 weeks. Pre-
vious pilot studies have demonstrated this dose is
efficacious and well-tolerated [28, 29]. The NAC and
Fig. 1 Trial Flow Diagram. NAC – N-Acetyl Cysteine; RT – Routine treatment; PCL-5 – PTSD Checklist 5
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placebo are either supplied as effervescent tablets or as
capsules. The trial medications will be supplied on a
monthly basis (to coincide with clinical interviews) and
participants will be instructed to return all packaging to
allow capsule counts by the trial monitor and the trial
pharmacist. Adherence will be assessed by pill counts of
returned medication packs. Participants will also be
required to complete a daily pill diary to document
treatment compliance. The trial medications will be sup-
plied, and returned containers counted, by the trial
pharmacist.
Blinding
To facilitate the double-blinding process, the trial medi-
cations (both NAC and placebo) will be dispensed in
identical numbers and tablet forms in sealed containers,
and the placebo containers will be specially treated with
microgram levels of NAC dust to produce its
characteristic smell. Placebo will be manufactured ac-
cording to European Medicine Agency (EMA) guide-
lines. We will require research workers to indicate if
they have become unblinded so that outcome assess-
ments can be undertaken by blinded assessors in
addition to any established treatments for their PTSD.
Follow-up assessments
Following baseline assessment and enrolment in the
trial, participants will be assessed with clinical interviews
at weeks 4, 8 and 12 of the trial. Post-trial interviews are
conducted at 16 weeks and 64 weeks to assess retention
of any treatment effects. At each follow-up assessment,
clinician-rated PTSD symptoms, and self-reported PTSD
symptoms as well as psychiatric comorbidities, quality of
life, substance use and somatic symptoms are assessed
(see Table 2). In between follow-up interviews (from
Baseline to Week 16), participants will complete weekly
Table 2 Primary and secondary outcomes according to time-point





















CAPS-5 (monthly version; 30-item observer rated
questionnaire, corresponding to the DSM-5
diagnosis for PTSD) [30]
X X X X
PTSD symptom severity CAPS-5 (weekly version) X X X X X
Secondary Outcomes
Depression & Anxiety HADS (14 item self-report screening measure of
anxiety and depression, designed for use in medical
settings) [31]
X X X X X X
HAM-D (17 item observer rated scale; evaluates
core symptoms of depression) [32]
Self-rated PTSD symptoms PCL-5 (20 item self-report measure of PTSD
symptoms) [33]
X X X X X X X X X X
Somatic symptoms PHQ-15 (15 item self-report measure of degree to
which one has been bothered by somatic symptoms
over the past month) [34]
X X X X X X
Quality of life WHO-QOL BREV (26 item measure of subjective
quality of life) [35]
X X X X X X
Alcohol use AUDIT (Participant answer ten-items relating to
frequency of symptoms and behaviours associated
with alcohol misuse) [36]
X X X X X X
Substance craving Visual Analogue Scale (to assess substance craving
over the past week. Participants will rate 5 items using
anchors of 0 (“not at all”) to 10 (“extreme” or “all the time”)
X X X X X X
Biomarkers of
oxidative stress






MINI V 5.0 (Semi-structured interview to assess habitual
substance use and psychiatric comorbidities, including
psychotic disorders) [37]
X
Demographic Information Questionnaire X
Adverse effects Self-report X X X
Indicates clinical interview
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self-report questionnaires regarding their PTSD symp-
toms. Follow-up interviews will take about 60 min to
complete; the weekly self-report questionnaire take ap-
proximately 5 min.
Outcomes
Our primary evaluation of treatment efficacy is the re-
duction of observer-rated PTSD symptom severity, oper-
ationalised as a reduction CAPS-5 severity scores.
Secondary objectives include evaluation of NAC to re-
duce self-reported symptoms of (1) PTSD, (2) depression
and anxiety, (3) substance use, (4) craving and (5) som-
atic symptoms. Evaluation of treatment efficacy will be
assessed over the entire trial period. Retention of treat-
ment effects will be assessed at weeks 16 and 64 post-
randomisation. The safety and tolerability of the inter-
vention will be evaluated by self-report.
Participants may elect to provide a blood sample at
baseline and Week 12 assessments. Blood based bio-
markers of oxidative stress will be evaluated as explora-
tory outcomes. Blood analysis will include measurement
of IL-6 (interleukin-6), TNF-alpha (tumour necrosis fac-
tor alpha), TBARS (thiobarbituric acid reactive sub-
stances), MDA (malondialdehyde) and BDNF (brain-
derived neurotrophic factor). Modulation of these blood-
based proteins will be correlated with treatment re-
sponse. Participants will not be fasting prior to the blood
collection. BD vacutainer SST II advance tubes (5 mL)
will be used to collect the sample and then allowed to
rest for 30 min prior to being centrifuged at 1300 g for
15 mins. The supernatant (serum) will be extracted and
aliquoted into 2 × 1.8 ml tubes. All samples will be stored
at − 80 degrees Celsius until tested.
Participant safety and withdrawal
Adverse effects will be assessed each week and reviewed
by the study team as well as the Data Safety Monitoring
Board, comprising the investigators. Though serious ad-
verse events with NAC are extremely rare, patients will
be advised to seek appropriate emergency medical help
in such an instance. For less serious events, participants
will be advised to contact their treating physician as
usual. Participants will be withdrawn from the trial
under the following conditions: (i) failure to take the
trial medication for seven consecutive days; (ii) cessation
of effective contraception or pregnancy; and (iii) with-
drawal of consent or emergence of adverse events (as de-
termined by the medical investigators or decision of the
participant). All data will be retained in the intention-to-
treat analysis.
Standardised medical care
Standard care for participants will involve their regular,
medical appointments at variable intervals. The
additional procedures involve meeting with the research
clinician in outpatients of the clinical services – where
possible to coincide with scheduled appointments – at
4-weekly intervals, where they will engage in a clinical
interview, and complete self-report questionnaire items.
Participants will also be asked to complete one self-
report questionnaire, each week on their own.
Interrater reliability
All research staff undertaking clinical assessments will be
trained in the assessments prior to commending recruit-
ment. All clinical research staff will undertake observed
interviews on a yearly basis to ensure compliance with
standardised administration guidelines and complete reli-
ability and inter-rater reliability assessments.
Statistical analysis
All analyses will be conducted by our independent trial
statistician and will include all randomised participants
with at least one post-baseline observation (modified
intention to treat). The statistician will be blind to group
allocation (triple blind design). Differences between
study arms at baseline will be assessed using either chi-
squared or Fisher’s exact test for categorical data and ei-
ther student t–test or Mann-Whitney U test for continu-
ous data. Non-parametric statistics will be used when
assumptions for parametric methods are violated. Effect
sizes will be calculated using Cohen’s guidelines. The
primary efficacy analysis will assess the impact of the
treatment on group differences for the primary outcome
measure (CAPS-5) over the entire study period and use
a likelihood based mixed-effects model, repeated mea-
sures approach (MMRM). The MMRM model includes
the categorical effects of treatment, investigator, visit,
and treatment-by-visit interaction, as well as the con-
tinuous, fixed covariates of baseline score and baseline
score-by-visit interaction.
Data handling and monitoring
Paper copies of the questionnaires will be kept in a
locked filing cabinet in the Department of Psychiatry of
the clinical services, in a room kept locked. The data will
be entered into a computer in re-identifiable form, with
the code kept in a separate file. Computer files will be
kept on a password-protected computer in the depart-
ment of psychiatry in a room kept locked at night. All
files will be kept for 15 years before secure disposal.
All blood samples will be securely stored at the Austin
Health Pathology Department in a monitored, trial spe-
cific freezer at − 80 degrees Celsius and labelled in a re-
identifiable format before being transferred to the Flory
Institute of Neuroscience and Mental Health for ana-
lysis. Following analysis, all blood will be securely
destroyed by the Flory Institute of Neuroscience and
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Mental Health. Blood samples collected for the purposes
of this study that are not transferred to the Flory Insti-
tute of Neuroscience and Mental Health for analysis will
be destroyed after a period of 7 years.
Discussion
This study described the design and methodology of the
first multi-centre, randomised, double-blind, placebo-
controlled 12-week trial evaluating the efficacy of NAC as
an adjuvant therapy in treatment-resistant PTSD. Despite
recent advancements in evidence-based interventions for
PTSD, many patients continue to suffer substantial re-
sidual symptoms post-treatment [13, 14, 38]. Accumulat-
ing evidence supports the potential efficacy of NAC in
symptom reduction and functional improvements across a
range of psychiatric and neurological disorders [26, 27,
39]. We hypothesise that when delivered as an adjuvant
therapy, NAC will reduce PTSD and related symptomatol-
ogy greater than treatment as usual.
Oral NAC is widely available over the counter as an
inexpensive nutritional supplement and has demon-
strated low rates of adverse effects [26, 39, 40]. These
factors support the use of NAC in clinical settings as a
safe, inexpensive, easily administered and non-invasive
supplementary treatment strategy for PTSD. However,
recommendations regarding the use of NAC in psychi-
atric disorders are limited by the small number, small
sample sizes and quality of existing studies [26]. As such,
large controlled trials assessing the efficacy of NAC in
specific disorders are essential to establish its efficacy.
The anticipated sample size of the present study is likely
to exceed many previous clinical studies [41], thus in-
creasing the statistical power and generalizability of the
study findings. The large sample size, and randomised
placebo-controlled design are significant methodological
strengths in the current study. A further strength is the
assessment of clinical outcomes at 4- and 52-weeks
post-trial completion. Previous clinical trials have pro-
duced mixed results regarding the retention of treatment
benefits of NAC in other psychiatric disorders, with
some effects either retaining or emerging at 4 weeks
post-trial completion and others being lost [29, 42].
While NAC has been implicated as an effective adjunct-
ive treatment for many psychiatric conditions, the mech-
anism of effect has not yet been fully elucidated. The
therapeutic effects of NAC are likely mediated via its abil-
ity to modulate numerous pathophysiological processes
including oxidative stress, neurogenesis and apoptosis,
mitochondrial dysfunction, neuroinflammation and dys-
regulation of glutamate and dopamine [26]. Determining
the underlying mechanisms of NAC in PTSD is helpful,
not only to understanding the underlying neurobiology of
the illness but to discover additional therapies that may
operate on similar pathophysiological pathways. Of key
interest in the current study is NAC’s ability to replenish
glutathione and thereby diminish oxidative stress and neu-
roinflammation, which are well established biomechan-
isms in PTSD and its other psychiatric comorbidities [16–
18]. While studies have speculated on the mechanisms of
action of NAC on psychiatric symptoms [26, 40] few have
directly assessed blood-based biomarkers of oxidative
stress and neuroinflammation in the context of treatment
with NAC. The inclusion of blood-based biomarkers of
oxidative stress and neuroinflammation is therefore a key
methodological advantage of the present study.
A final advantage for this study is the heterogeneity of
the sample. The broad inclusion and limited exclusion
criteria mean that participants experiencing a range of
psychiatric comorbidities will be eligible, and the adju-
vant approach means that it will be available to most in-
dividuals with PTSD. To overcome the lack of specificity
incurred by the more ecologically valid inclusion criteria,
this study will thoroughly characterise psychiatric co-
morbidities and medical histories at baseline, so as to be
able to distinguish whether treatment responses vary be-
tween presentations. Use of the gold standard CAPS-5
PTSD diagnostic tool will also enable the study to char-
acterise trauma histories, and establish whether treat-
ment responses differ between trauma types. This is
particularly important, given that PTSD symptom sever-
ity and treatment response rates may differ between
those with a history of prolonged developmental trauma
and those with combat related PTSD [43–46].
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